|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 28, 2010 ) Minneapolis, MN – MEGASTOCKPICKS.COM a reputable stock and financial website specializing in undervalued penny stocks trading on the Pinks/OTC, OTCBB, AMEX, Nasdaq and NYSE has just initiated coverage on five pharmaceutical penny stocks.
www.megastockpicks.com can see substantial value in EntreMed Inc. (NASDAQ:ENMD) pipeline. Mr. Alexander from Mega Stock Picks was quoted as saying “ENMD reminds us a lot of like KERX did when we picked it as a strong buy at .18 cents, in fact we like EntreMed’s pipeline even better”
About ENMD:
” EntreMed, Inc. (EntreMed) is is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. The Company focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. The Company has four compounds in clinical development with a pipeline of orally-active, multi-mechanism drugs for the treatment of cancer including; MKC-1, a cell cycle inhibitor, Panzem (2-methoxyestradiol or 2ME2), and ENMD-1198, an antimitotic agent. EntreMed also has active investigational new drug (IND) for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076, and Panzem for rheumatoid arthritis.”
WWW.MEGASTOCKPICKS.COM rates EntreMed Inc. (NASDAQ:ENMD) a “Strong Buy” with a one year price target of $3.00
Mega Stock Picks have also rated Cell Therapeutics Inc. (NASDAQ:CTIC), Bionovo Inc. (NASDAQ:BNVI), Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) and NexMed Inc. (NASDAQ:NEXM) as “Buys” and stocks to keep an eye on.
About CTIC:
Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. The Company is focused on developing pixantrone, OPAXIO, brostallicin and bisplantinates. Pixantrone is an anthracycline derivative, for the treatment of non-HodgkinÂ’s lymphoma (NHL), and various other hematologic malignancies, solid tumors and immunological disorders. The Company is developing OPAXIO (paclitaxel poliglumex), is a maintenance therapy for women with advanced stage ovarian cancer. Brostallicin is a synthetic Deoxyribonucleic Acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity. In March 2009, the Company sold its 50% interest in RIT Oncology.
To sign up for daily hot stock alerts, visit www.megastockpicks.com
About www.megastockpicks.com
megastockpicks.com offers a FREE penny stock newsletter with live updates. Megastockpicks.com is a leading stock web site that provides free alerts on stocks that are making big gains, as well as our weekly Newsletter.
megastockpicks.com is an independent electronic publication that provides information on selected publicly traded companies. Megastockpicks.com is not a registered investment advisor or broker dealer. Megastockpicks.comÂ’s affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. We have not been compensated in any way for this report.
Mega Stock Picks
Thomas Alexander
651-442-4255
megastockpicks@gmail.com 
Source: EmailWire.com
|
|
|
|
